The role of non-invasive imaging and cell labelling techniques in the clinical assessment of stem cell therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Non-invasive imaging can play several potential roles in cardiac regenerative therapy. In preclinical models, postmortem evaluation, both grossly and microscopically, can be performed to determine therapeutic efficacy. However, in cardiac clinical trials of stem cell therapy, obtaining cardiac tissue for sampling, such as from biopsy, is rarely performed due to the invasive nature. Thus, many preclinical studies have employed traditional imaging techniques to measure cardiac morphology, function, perfusion, and flow by echocardiography, radionuclide imaging, and/or cardiovascular magnetic resonance imaging (MRI) to optimize stem cell therapy protocols. These imaging studies provide surrogate measures of morbidity and mortality for measuring the success of cellular therapies in clinical trials. Recently, cellular labeling methods have been extended to the many types of stem cells in animal models of cardiovascular disease that open new avenues for cell targeting and tracking in combination with these non-invasive imaging techniques. It can be envisioned that cellular labeling techniques will be extended to cardiovascular stem cell clinical trials in the near future to enhance the interpretation of both negative and positive outcomes and ultimately for the tailoring of stem cell therapies to individual patients.

Original languageEnglish (US)
Title of host publicationRebuilding the Infarcted Heart
PublisherCRC Press
Pages135-153
Number of pages19
ISBN (Electronic)9780203089736
ISBN (Print)9780415419246
StatePublished - Jan 1 2007

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Clinical Trials
Cell Tracking
Radionuclide Imaging
Echocardiography
Cardiovascular Diseases
Therapeutics
Animal Models
Perfusion
Magnetic Resonance Imaging
Morbidity
Biopsy
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The role of non-invasive imaging and cell labelling techniques in the clinical assessment of stem cell therapy. / Kraitchman, Dara.

Rebuilding the Infarcted Heart. CRC Press, 2007. p. 135-153.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{5b7777d6db3c4af28638f4ef4bd56ed2,
title = "The role of non-invasive imaging and cell labelling techniques in the clinical assessment of stem cell therapy",
abstract = "Introduction Non-invasive imaging can play several potential roles in cardiac regenerative therapy. In preclinical models, postmortem evaluation, both grossly and microscopically, can be performed to determine therapeutic efficacy. However, in cardiac clinical trials of stem cell therapy, obtaining cardiac tissue for sampling, such as from biopsy, is rarely performed due to the invasive nature. Thus, many preclinical studies have employed traditional imaging techniques to measure cardiac morphology, function, perfusion, and flow by echocardiography, radionuclide imaging, and/or cardiovascular magnetic resonance imaging (MRI) to optimize stem cell therapy protocols. These imaging studies provide surrogate measures of morbidity and mortality for measuring the success of cellular therapies in clinical trials. Recently, cellular labeling methods have been extended to the many types of stem cells in animal models of cardiovascular disease that open new avenues for cell targeting and tracking in combination with these non-invasive imaging techniques. It can be envisioned that cellular labeling techniques will be extended to cardiovascular stem cell clinical trials in the near future to enhance the interpretation of both negative and positive outcomes and ultimately for the tailoring of stem cell therapies to individual patients.",
author = "Dara Kraitchman",
year = "2007",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780415419246",
pages = "135--153",
booktitle = "Rebuilding the Infarcted Heart",
publisher = "CRC Press",
address = "United States",

}

TY - CHAP

T1 - The role of non-invasive imaging and cell labelling techniques in the clinical assessment of stem cell therapy

AU - Kraitchman, Dara

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Introduction Non-invasive imaging can play several potential roles in cardiac regenerative therapy. In preclinical models, postmortem evaluation, both grossly and microscopically, can be performed to determine therapeutic efficacy. However, in cardiac clinical trials of stem cell therapy, obtaining cardiac tissue for sampling, such as from biopsy, is rarely performed due to the invasive nature. Thus, many preclinical studies have employed traditional imaging techniques to measure cardiac morphology, function, perfusion, and flow by echocardiography, radionuclide imaging, and/or cardiovascular magnetic resonance imaging (MRI) to optimize stem cell therapy protocols. These imaging studies provide surrogate measures of morbidity and mortality for measuring the success of cellular therapies in clinical trials. Recently, cellular labeling methods have been extended to the many types of stem cells in animal models of cardiovascular disease that open new avenues for cell targeting and tracking in combination with these non-invasive imaging techniques. It can be envisioned that cellular labeling techniques will be extended to cardiovascular stem cell clinical trials in the near future to enhance the interpretation of both negative and positive outcomes and ultimately for the tailoring of stem cell therapies to individual patients.

AB - Introduction Non-invasive imaging can play several potential roles in cardiac regenerative therapy. In preclinical models, postmortem evaluation, both grossly and microscopically, can be performed to determine therapeutic efficacy. However, in cardiac clinical trials of stem cell therapy, obtaining cardiac tissue for sampling, such as from biopsy, is rarely performed due to the invasive nature. Thus, many preclinical studies have employed traditional imaging techniques to measure cardiac morphology, function, perfusion, and flow by echocardiography, radionuclide imaging, and/or cardiovascular magnetic resonance imaging (MRI) to optimize stem cell therapy protocols. These imaging studies provide surrogate measures of morbidity and mortality for measuring the success of cellular therapies in clinical trials. Recently, cellular labeling methods have been extended to the many types of stem cells in animal models of cardiovascular disease that open new avenues for cell targeting and tracking in combination with these non-invasive imaging techniques. It can be envisioned that cellular labeling techniques will be extended to cardiovascular stem cell clinical trials in the near future to enhance the interpretation of both negative and positive outcomes and ultimately for the tailoring of stem cell therapies to individual patients.

UR - http://www.scopus.com/inward/record.url?scp=85056556841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056556841&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85056556841

SN - 9780415419246

SP - 135

EP - 153

BT - Rebuilding the Infarcted Heart

PB - CRC Press

ER -